Skip to main content
. 2013 Oct 2;13:455. doi: 10.1186/1471-2334-13-455

Table 5.

Non-susceptibility rates of the most prevalent non-invasive bacterial pathogens from Gabon

Pathogen (n) Antimicrobial non-susceptibility (%)
PEN/AMPa COX AMP + BLI CRO GEN CIP CHL CLI ERY SXT TCY
S. aureus (312)
94.2
8.33
8.33
8.33
2.3
9.4
0.9
2.5
17.0
8.3
37.5
S. pyogenes (69)
8.6
-
-
0
-
-
9.1
7.8
7.9
56.0
-
S. pneumoniae (19)
6.7
-
-
ND
-
-
14.3
10.5
11.1
82.4
ND
E. faecalis (19)
0
-
-
-
-
81.3
-
-
-
-
-
K. pneumoniae (56)
100
-
51.9
38.9
38.2
21.4
55.6
-
-
60
ND
P. agglomerans (6)
83.3
-
75.5
ND
0
0
ND
-
-
0
ND
P. aeruginosa (39)
-
-
0b
0c
0d
2.6
-
-
-
-
-
P. mirabilis (52)
34.6
-
17.3
2.1
13.5
1.9
44.4
-
-
48.9
ND
E. coli (114)
80.4
-
60.3
16.4
14.7
24.1
35.5
-
-
88.1
ND
S. enterica (9) 22.2 - ND 0 0 0 0 - - 12.5 0

Note: Abbrevations are penicillin/ampicillin (PEN/AMP), cefoxitin (COX), ampicillin plus betalactamase-inhibitor (AMP + BLI), ceftriaxone (CRO), gentamicin (GEN), ciprofloxacin (CIP), chloramphenicol (CHL), clindamycin (CLI), erythromycin (ERY), cotrimoxazole (SXT), tetracycline (TCY), not done (ND). Non-susceptible isolates are shown as the percentage of tested isolates.

aShown is the non-susceptibility of Gram-positives to penicillin and the non-susceptibility of Gram-negatives and E. faecalis to ampicillin.

bNon-susceptibility to piperacillin/tazobactam.

cNon-susceptibility to ceftazidim.

dNon-susceptibility to amikacin.